» Articles » PMID: 29629068

MyD88 in Antigen-presenting Cells is Not Required for CD4+ T-cell Responses During Peptide Nanofiber Vaccination

Overview
Journal Medchemcomm
Specialty Chemistry
Date 2018 Apr 10
PMID 29629068
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Self-assembled peptide nanofibers raise significant antibody and T cell responses without adjuvants, but the mechanism by which they achieve this has not been fully elucidated. Myeloid differentiation primary response gene 88 (MyD88) previously has been shown to be critical for the antibody response to antigens presented by peptide nanofibers. The present study sought to determine the cell subset in which MyD88 is essential for T cell responses. Mice deficient in MyD88 or CD11c cells had severely attenuated T cell responses. However, mice lacking MyD88 in only CD11c cells remained capable of internalizing, processing, and presenting nanofiber-derived epitopes to stimulate T cell responses. The necessity of inflammasome pathway was ruled out. Using adoptive transfer models where MyD88 was eliminated in CD4 T cells or in the host, we observed that deficiency only in T cells or only in the host had no impact on the T cell response to nanofiber vaccines. Therefore, knocking out MyD88 in either antigen presenting cells (APCs) or CD4 T cells could not compromise the CD4 T cell responses, suggesting that self-assembled peptide nanofibers trigger redundant MyD88-dependent and MyD88-independent signaling pathways in APCs and T cells. Similar redundancy has been observed for other adjuvants, and this is discussed.

Citing Articles

Lung cDC1 and cDC2 dendritic cells priming naive CD8 T cells in situ prior to migration to draining lymph nodes.

Si Y, Wang Y, Tian Q, Wang Q, Pollard J, Srivastava P Cell Rep. 2023; 42(10):113299.

PMID: 37864794 PMC: 10676754. DOI: 10.1016/j.celrep.2023.113299.


The role of dendritic cells in the immunomodulation to implanted biomaterials.

Wang S, Chen Y, Ling Z, Li J, Hu J, He F Int J Oral Sci. 2022; 14(1):52.

PMID: 36333287 PMC: 9636170. DOI: 10.1038/s41368-022-00203-2.


Peptide-based supramolecular vaccine systems.

ONeill C, Shrimali P, Clapacs Z, Files M, Rudra J Acta Biomater. 2021; 133:153-167.

PMID: 34010691 PMC: 8497425. DOI: 10.1016/j.actbio.2021.05.003.


Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and T17 responses.

Si Y, Tian Q, Zhao F, Kelly S, Shores L, Camacho D Sci Adv. 2020; 6(32):eaba0995.

PMID: 32821819 PMC: 7413739. DOI: 10.1126/sciadv.aba0995.


Supramolecular Peptide Assemblies as Antimicrobial Scaffolds.

Simonson A, Aronson M, Medina S Molecules. 2020; 25(12).

PMID: 32545885 PMC: 7355828. DOI: 10.3390/molecules25122751.

References
1.
Pasare C, Medzhitov R . Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol. 2005; 560:11-8. DOI: 10.1007/0-387-24180-9_2. View

2.
Schnare M, BARTON G, Holt A, Takeda K, Akira S, Medzhitov R . Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001; 2(10):947-50. DOI: 10.1038/ni712. View

3.
Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S . MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell. 1998; 2(2):253-8. DOI: 10.1016/s1097-2765(00)80136-7. View

4.
Rappuoli R, Mandl C, Black S, De Gregorio E . Vaccines for the twenty-first century society. Nat Rev Immunol. 2011; 11(12):865-72. PMC: 7098427. DOI: 10.1038/nri3085. View

5.
Chen J, Pompano R, Santiago F, Maillat L, Sciammas R, Sun T . The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. Biomaterials. 2013; 34(34):8776-85. PMC: 3814015. DOI: 10.1016/j.biomaterials.2013.07.063. View